Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from China-based <a href="https://www.smartkarma.com/entities/8045" target="_blank" data-smartkarma-citation="entities:8045:1">Shanghai Fosun Pharmaceutical (Group) (2196 HK)</a>. In this insight, we will cover the company's background, its growth drivers, financial highlights, and score the deal in our ECM Framework. </p>

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from China-based Shanghai Fosun Pharmaceutical (Group) (2196 HK). In this insight, we will cover the company's background, its growth drivers, financial highlights, and score the deal in our ECM Framework. 

Sisram Medical IPO: Israeli Technology, China Story

United States

Lumenis Ltd. manufactures and sells laser and light-based systems, as well as accessories for surgical, aesthetic, and ophthalmic applications. The Company provides a range of laser and intense pulsed light products for use in benign prostatic hyperplasia, urinary lithotripsy, gynecology, general surgery, dermatology, hair removal, acne, and various retinal pathologies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lumenis Ltd (LMNS US)

Sisram Medical IPO: Israeli Technology, China Story

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)